Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

Dolutegravir (S/GSK1349572) With Multivitamins or Acid Reducing Agents

July/August 2011

Dolutegravir (S/GSK1349572) is an unboosted, once-daily, next-generation HIV integrase inhibitor. The effects of multivitamins (One-A-Day Maximum, single tablet), antacid (Maalox 20 mL single dose with or 2 hours after dolutegravir) and omeprazole (40 mg once daily for 5 days) on single doses of dolutegravir (50 mg) were studied in HIV-negative subjects.

Coadministration of the multivitamin modestly decreased dolutegravir AUC and Cmax by 33% and 35%, respectively. Concurrent antacid co-administration reduced dolutegravir AUC and Cmax by 74% and 72%, respectively. Staggered antacid dosing significantly diminished this interaction, with a reduction in dolutegravir AUC of 26% and Cmax of 18%. Omeprazole did not significantly affect dolutegravir exposure (no change in AUC, 9% decrease in Cmax).

Dolutegravir can be taken with proton pump inhibitors and multivitamins without dose adjustment but should be administered 2 hours before or 6 hours after antacids. The mechanism of the antacid interaction with dolutegravir is likely to result from chelation with metal cations in the antacid rather than an effect of pH and would be consistent with the omeprazole data.

Source: hiv-druginteractions.org (23 June 2011).

Ref: Patel P et al. Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers. J Antimicrob Chemother, 2011, 66(7): 1567-1572.

Links to external websites are current at time of posting but not maintained.



  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
 
See Also
More on HIV Medications
Other Integrase Inhibitors
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement